Passage Bio, Inc. (PASG)

22.82 -4.49 (-16.44%) At close: 4:00PM EST

Passage Bio, Inc.

Two Commerce Square
28th Floor 2001 Market Street
Philadelphia, PA 19103
United States
267 866 0311
http://www.passagebio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 20

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Bruce A. Goldsmith M.B.A., Ph.D.	CEO, Pres & Director	485.72k	N/A	1966
Dr. Stephen P. Squinto	Co-Founder, Acting Head of R&D and Director	786.99k	N/A	1956
Ms. Jill M. Quigley J.D.	Chief Operating Officer	756.38k	N/A	1976
Dr. Gary Romano M.D., Ph.D.	Chief Medical Officer	519.77k	N/A	1962
Dr. James M. Wilson M.D., Ph.D.	Co-Founder & Chief Scientific Advisor	N/A	N/A	1955
Mr. Richard S. Morris	Chief Financial Officer	N/A	N/A	1974
Mr. Alexandros Fotopoulos MSc, MBA	Chief Technical Officer	N/A	N/A	1969
Mr. Edgar B. Cale Esq., J.D.	Gen. Counsel & Company Sec.	N/A	N/A	1964
Robin DeRogatis	VP HR	N/A	N/A	N/A

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. The company develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase (ß-gal) for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin for the treatment of FTD caused by a deficiency of progranulin; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase, for infantile Krabbe disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.

Corporate Governance

Passage Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.